Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of October 2025. The filing details a share repurchase executed on October 1, 2025, acting through BNP Paribas SA as the broker. The transaction is part of the Company's existing buyback programme, effected pursuant to a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and capital structure updates. It does not contain revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (Oct 1, 2025): 262,000 ordinary shares.
- Price Range (GBp): Lowest 1,594.50p; Highest 1,670.00p.
- Volume-Weighted Average Price (GBp): 1,626.49p.
- Total Shares Purchased (Since Sept 30, 2025): 567,000 ordinary shares.
- Treasury Shares Held: 248,031,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,067,375,496 ordinary shares.
- Total Voting Rights: 4,067,375,496.
- Treasury Voting Rights Percentage: 6.10%.
Material Changes
Following the purchase on October 1, 2025, the Company's treasury share count increased to 248,031,844. Consequently, the number of ordinary shares in issue (excluding treasury shares) stands at 4,067,375,496. The percentage of voting rights attributable to treasury shares is confirmed at 6.10% in accordance with DTR 5.5.1R.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q2 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares in issue (4,067,375,496) for calculating ownership thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the current percentage of voting rights held in treasury (6.10%) to assess dilution or control implications.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining scope of the buyback programme.
- Check the 2024 Form 20-F and Q2 2025 results for the specific risk factors referenced in the cautionary statement.